| UHC Commercial Medical & Drug | Brineura® (Cerliponase Alfa) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Buprenorphine (Brixadi® & Sublocade®) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Hereditary Angioedema (HAE), Treatment and Prophylaxis – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Ilaris® (Canakinumab) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Intracanalicular and Intravitreal Corticosteroid Implants – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Krystexxa® (Pegloticase) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Self-Administered Medications – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Commercial Medical & Drug | Synagis® (Palivizumab) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| Ambetter Health Alabama Clinical | Concert Genetics Oncology: Algorithmic Assays (V2.2025) | 2025-11-01 |
| Ambetter Health Alabama Clinical | Concert Genetics Oncology: Cancer Screening and Surveillance (V2.2025) | 2025-11-01 |